Vincula Biotech Group is a biotechnology ecosystem, covering the entire chain of regenerative medicine and cell & gene therapy.
We are a unique platform of research laboratories, biobanks, manufacturing facilities, authorized clinics and hospitals, which are led by world-renowned experts, working in synergy and with the same ethical goal: to bring the benefits of regenerative medicine and cell & gene therapy to all, by transforming innovative treatments into effective, standardized, personalized and accessible therapies.
As the first privately-owned biotechnology group of its kind, we seamlessly integrate all the processes under centralized leadership and add the advantages of business logic and efficient project and financial management to this field. Vincula Biotech Group is the champion in unlocking the potential of regenerative medicine and bringing its benefits to daily medical practice.
We are a unique platform of research laboratories, biobanks, manufacturing facilities, authorized clinics and hospitals, which are led by world-renowned experts, working in synergy and with the same ethical goal: to bring the benefits of regenerative medicine and cell & gene therapy to all, by transforming innovative treatments into effective, standardized, personalized and accessible treatments.
As the first privately-owned biotechnology group of its kind, we seamlessly integrate all the processes under centralized leadership and add the advantages of business logic and efficient project and financial management to this field. Vincula Biotech Group is the champion in unlocking the potential of regenerative medicine and bringing its benefits to daily medical practice.
As the first privately-owned biotechnology group of its kind, we seamlessly integrate all the processes under centralized leadership and add the advantages of business logic and efficient project and financial management to this field. Vincula Biotech Group is the champion in unlocking the potential of regenerative medicine and bringing its benefits to daily medical practice.
We are a unique platform of research laboratories, biobanks, manufacturing facilities, authorized clinics and hospitals, which are led by world-renowned experts, working in synergy and with the same ethical goal: to bring the benefits of regenerative medicine and cell & gene therapy to all, by transforming innovative treatments into effective, standardized, personalized and accessible treatments.
Our Team
OUR TEAM
HEALTHCARE
Medical experts
Academician Prof. Aleksandar Ljubić, MD, PhD
Džihan Abazović, MD
Prof. Dušan Marić, PhD
Scientific experts
Prof. Miomir Knežević, PhD
Prof. Stephen Minger, PhD
Prof. Mia Rakić, D.D.S. PhD
Prof. Danilo Vojvodić, PhD
Healthcare
BIOCELL HOSPITAL
Belgrade, Serbia
Established in 2022
General hospital featuring all specialities, cutting-edge technology, focusing on regenerative medicine, including cell & gene therapies.
PARKS HOSPITAL
Novi Sad, Serbia
Established in 1993
Specialized surgical center combining standard medical treatments with the latest advancements in surgery.
Our healthcare facilities are home to the leading experts and healthcare professionals. They are equipped with state-of-the-art diagnostic and procedure technologies, with premium patient care and accommodation.
Manufacturing & Services
EDUCELL
Trzin, Slovenia
Established in 1997
Speciality: biotechnology development and manufacturing of cell products and medical devices, GMP certified processes
BIOBANKA
Trzin, Slovenia
Established in 2008
Speciality: cryopreservation of blood, cells and tissues
Cell and tissue collection
and cryopreservation
(Stem cells and MSCS sources)
- Umbilical cord
- Dental pulp
- Adipose tissue
- Bone marrow
- Biopsy material
Cell manipulation
(Manufacturing)
- MSCs manufacturing – research & GMP grade
- CAR-T & TILs manufacturing, through OMPUL POC units
Protocols
- Segova, SEGO, SEMPRE RB
- Autologous cell therapy, PRP, ORT-ART
- CAR-T, TILs, MSCs
Research
BIO INSTITUTE
Basic and clinical research of the entire Group is centralized at Bio Institute. Here, modern hypotheses are examined and tested with the aim to bring the most recent discoveries to medical practice.
ADVANTAGES
- Top equipped laboratories
- Access to clinical data, publications & experts (scientific & medical committees)
- Admin support for clinical trials, IP management, grant application, publications
PROJECT MANAGEMENT
- Basic research
- Pre-clinical data & clinical trials
- Product development (devices, services, protocols)
FIELDS OF RESEARCH
- Orthopedics
- Neurodegenerative disorders
- Endocrinology
- Gynecology
Projects & Publications
SELECTED PROJECTS
| GIMA | In vitro maturation of human oocytes | ||
|---|---|---|---|
| SEGOVA | Treatment of human gonadal tissue with autologous stem cell and stem cells products | ||
| BTOA | Biological therapy of autism | ||
| CABG BRF | In vivo treatment of patients with Bio Regenerative Fibrin | ||
| BTOCP | Biological treatment of cerebral palsy | ||
SELECTED PUBLICATIONS
| Tinjić S, Abazović D, Ljubić D, Vojvodić D, Božanović T, Ibrišimović M, Marković S, Ljubić A. Influence of Autologous In Vitro Activation of Ovaries by Stem Cells and Growth Factors on Endocrine and Reproductive Function of Patients with Ovarian Insufficiency-A Clinical Trial Study. Int J Fertil Steril. 2021 Jul;15(3):178-188. |
| Micovic S, Everts P, Calija B, Strugarevic E, Grubor N, Boricic M, Lesanovic J, Box H, Abazovic D. Novel autologous, high concentrated fibrin as advanced hemostatic agent for coronary surgery. Transfus Apher Sci. 2021 Aug;60(4):103171. |
| Veber M, Vogler J, Knežević M, Barlič A, Drobnič M. Combination of Filtered Bone Marrow Aspirate and Biomimetic Scaffold for the Treatment of Knee Osteochondral Lesions: Cellular and Early Clinical Results of a Single Centre Case Series. Tissue Eng Regen Med. 2020 Jun;17(3):375-386. |
| Česen Mazič M, Girandon L, Kneževič M, Avčin SL, Jazbec J. Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells-Single Center Experience. Front Bioeng Biotechnol. 2018 Jul 24;6:93. |
| Maric DM, Milankov Z, Kojić V, Jakimov D, Abazovic D, Marić DL, Bansal H. Impact of the Fibroblast Morphogenetic Field Information on Human Healthy and Tumor Cell . J Stem Cell . 2017Jan;12:91–103. |
Contact Us
Get in touch and join us on the exciting journey of unlocking the potential of regenerative medicine and cell&gene therapies.
office@vinculabiotech.com
